ArticleInternational journal of pharmaceutics: X2025
Co-assembled
Article in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The self-assembly mechanisms of glycyrrhizic acid: Permeation enhancement and transdermal applications.International journal of pharmaceutics: X · 2026Review
- Self-Assembled Nanoparticles of Licorice Extract Enhance Skin Penetration and Regulate Barrier Proteins via a Dual-Channel Pathway.Pharmaceutics · 2026Article
- CD276-directed supramolecular nanoplatform with pH-triggered gemcitabine release for potent tumor stromal and vascular suppression.International journal of pharmaceutics: X · 2025Article
- Pharmacological Potentials and Delivery Strategies of Isoliquiritigenin: Challenges and Advances in Enhancing Bioavailability.Drug design, development and therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Licochalcone A (LA) garnered remarkable acclaim in acute inflammation therapy, however, poor release capability from the matrix and oral bioavailability restrict its oral delivery. To address this challenge, licorice-derived glycyrrhizic acid (GA) and LA were co-assembled into GA-LA (GLA) binary co-assembled
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.